LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer

Though TRAIL has been hailed as a promising drug for tumour treatment, it has been observed that many tumour cells have developed escape mechanisms against TRAIL-induced apoptosis. As a receptor of LPS, TLR 4, which is expressed on a variety of cancer cells, can be associated with TRAIL-resistance o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Beyer, Katharina (VerfasserIn) , Weiß, Frank Ulrich (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2017
In: Infectious agents and cancer
Year: 2017, Jahrgang: 12
ISSN:1750-9378
DOI:10.1186/s13027-017-0139-4
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1186/s13027-017-0139-4
Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13027-017-0139-4
Volltext
Verfasserangaben:Katharina Beyer, Lars Ivo Partecke, Felicitas Roetz, Herbert Fluhr, Frank Ulrich Weiss, Claus-Dieter Heidecke and Wolfram von Bernstorff
Beschreibung
Zusammenfassung:Though TRAIL has been hailed as a promising drug for tumour treatment, it has been observed that many tumour cells have developed escape mechanisms against TRAIL-induced apoptosis. As a receptor of LPS, TLR 4, which is expressed on a variety of cancer cells, can be associated with TRAIL-resistance of tumour cells and tumour progression as well as with the generation of an anti-tumour immune response.
Beschreibung:Published: 30 May 2017
Gesehen am 14.06.2018
Beschreibung:Online Resource
ISSN:1750-9378
DOI:10.1186/s13027-017-0139-4